Medtronic plc News
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
see moreMedtronic plc Market News
9d
Medtronic's Strategic Moves and Financial Performance in 2026
- Medtronic's 2026 financial results and strategic initiatives.
25d
Medtronic's Recent Developments: Financial Performance and Product Recall
Medtronic's stock performance and product recall impact analyzed.
28d
Strong Fourth Quarter Boosts Medtronic's Stock Amid Mixed Analyst Opinions
An overview of Medtronic's recent financial results and stock performance.
19 Jul at 18:11
Medtronic Achieves Record Revenue Growth as Stock Faces Mixed Analyst Ratings
An overview of Medtronic's latest financial results and stock performance.
12 Jul at 18:09
Medtronic's Recent Financial Performance and Market Movements
An overview of Medtronic's recent financial results and stock performance.
07 Jul at 04:57
Medtronic's Recent Developments: Cybersecurity Breach and Medicare's Health Tech Initiative
Medtronic faces a data breach and Medicare's new health tech pilot program.
05 May at 14:39
Medtronic: 9M Records Stolen; MiniMed IPO, UBS Cut
This week Medtronic faced a 9‑million‑record breach and an analyst price‑target cut tied to MiniMed’s IPO dilution. Combined with an institutional stake reduction and an upcoming FTC approval/Investor Day catalyst, these concrete developments create near‑term headwinds for MDT while leaving core product operations reportedly intact.